Loading stock data…
RZLT
$3.30+0.10 (+3.13%)
Market ClosedLast close May 1
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rezolute, Inc. in the Healthcare sector is trading at $3.30. The stock is currently 71% below its 52-week high of $11.46, remaining 41.5% below its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why RZLT maintains its current current market pressure. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.30
Potential Upside
5%
Whystock Fair Value$3.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$318.67M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.80%
Volume
Today's trading volume
1.47M
Recent News
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement
Neurocrine’s rare-disease push, anchored by Soleno’s VYKAT XR, reshapes biotech dealmaking focus, today, April 6, 2026.
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
XOMA Royalty Q4 Earnings Call Highlights
XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig
Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing
Rezolute Inc. (NASDAQ:RZLT) is one of the best biotech penny stocks to buy according to analysts. On December 11, Rezolute released topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism/HI. The study, which included 63 participants aged 3 months to 45 years across more than a dozen countries, did […]
Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They Bought
Insiders bought these stocks heavily in 2025, but investors should be wary; only some of them are good buys for 2026 portfolios.